<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="16%"></col>
<col width="84%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Meperidine is contraindicated in patients who are receiving monoamine oxidase</paragraph>
<paragraph>(MAOIs) or those who have recently received such agents. Therapeutic doses of</paragraph>
<paragraph>meperidine have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. The mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. Some have been characterized by coma, severe respiratory depression, cyanosis, and hypotension, and have resembled the syndrome of acute narcotic overdose. Serotonin syndrome with agitation, hyperthermia, diarrhea, tachycardia, sweating, tremors and impaired consciousness may also occur. In other reactions the predominant manifestations have been hyperexcitability, convulsions, tachycardia, hyperpyrexia, and hypertension.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td align="justify" stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Do not use meperidine hydrochloride tablets in patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
<paragraph>Intravenous hydrocortisone or prednisolone have been used to treat severe reactions, with the addition of intravenous chlorpromazine in those cases exhibiting hypertension and hyperpyrexia. The usefulness and safety of narcotic antagonists in the treatment of these reactions is unknown.)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Inhibitors of CYP3A4 and CYP2B6</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of meperidine hydrochloride tablets and CYP3A4 or CYP2B6 inhibitors can increase the plasma concentration of meperidine, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of meperidine hydrochloride tablets and CYP2B6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of meperidine hydrochloride tablets is achieved <content stylecode="italics">[see <linkhtml href="#ID_17aa3d18-4242-4ca5-acab-9b1f6a4eb600">Warnings and</linkhtml>
<linkhtml href="#ID_17aa3d18-4242-4ca5-acab-9b1f6a4eb600">Precautions</linkhtml> (<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">5.4</linkhtml>)]</content>.</paragraph>
<paragraph>After stopping a CYP3A4 or CYP2B6 inhibitor, as the effects of the inhibitor decline,</paragraph>
<paragraph>the meperidine plasma concentration will decrease <content stylecode="italics">[see <linkhtml href="#ID_59a892ba-4291-4176-a619-cfcefd5d6cb4">Clinical</linkhtml>
<linkhtml href="#ID_59a892ba-4291-4176-a619-cfcefd5d6cb4">Pharmacology</linkhtml> (<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to meperidine.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>If concomitant use is necessary, consider dosage reduction of meperidine hydrochloride tablets until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.</paragraph>
<paragraph>If a CYP3A4 or CYP2B6 inhibitor is discontinued, consider increasing the meperidine hydrochloride tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir)</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">CYP3A4 and CYP2B6 Inducers</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of meperidine hydrochloride tablets and CYP3A4 or CYP2B6 inducers can decrease the plasma concentration of meperidine <content stylecode="italics">[see <linkhtml href="#ID_59a892ba-4291-4176-a619-cfcefd5d6cb4">Clinical Pharmacology</linkhtml> (<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">12.3</linkhtml>)]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to meperidine <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#ID_17aa3d18-4242-4ca5-acab-9b1f6a4eb600">Warningsand Precautions</linkhtml>
</content>
<content stylecode="italics"> (<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">5.4</linkhtml>)]</content>.</paragraph>
<paragraph>After stopping a CYP3A4 or CYP2B6 inducer, as the effects of the inducer decline, the meperidine plasma concentration will increase <content stylecode="italics">[see <linkhtml href="#ID_59a892ba-4291-4176-a619-cfcefd5d6cb4">Clinical</linkhtml>
<linkhtml href="#ID_59a892ba-4291-4176-a619-cfcefd5d6cb4">Pharmacology</linkhtml> (<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">12.3</linkhtml>)]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>If concomitant use is necessary, consider increasing the meperidine hydrochloride tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 or CYP2B6 inducer is discontinued, consider meperidine hydrochloride tablets dosage reduction and monitor for signs of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Rifampin, carbamazepine, phenytoin</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see <linkhtml href="#ID_17aa3d18-4242-4ca5-acab-9b1f6a4eb600">Warnings and Precautions</linkhtml> (<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">5.5</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content stylecode="italics">[see <linkhtml href="#ID_17aa3d18-4242-4ca5-acab-9b1f6a4eb600">Warnings and</linkhtml>
<linkhtml href="#ID_17aa3d18-4242-4ca5-acab-9b1f6a4eb600">Precautions</linkhtml>
<linkhtml href="https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d714a877-5fce-4dd2-ba64-7f88004da0a5&amp;type=display">5.8</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue meperidine hydrochloride tablets if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>May reduce the analgesic effect of meperidine hydrochloride tablets and/or precipitate withdrawal symptoms.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Avoid concomitant use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Meperidine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of meperidine hydrochloride tablets and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Anticholinergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when meperidine hydrochloride tablets is used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Acyclovir</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of acyclovir may increase the plasma concentrations of meperidine and its metabolite, normeperidine.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule ">
<paragraph>If concomitant use of acyclovir and meperidine hydrochloride tablets is necessary, monitor patients for respiratory depression and sedation at frequent intervals.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="bold">Cimetidine</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule ">
<paragraph>The concomitant use of cimetidine may reduce the clearance and volume of distribution of meperidine also the formation of the metabolite, normeperidine, in healthy subjects.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>If concomitant use of cimetidine and meperidine hydrochloride tablets is necessary, monitor patients for respiratory depression and sedation at frequent intervals.</paragraph>
</td>
</tr>
</tbody>
</table>